Diabetes mellitus and atherosclerosis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Diabetes mellitus is one of main risk factor of atherosclerosis. Development of dislipoproteinemia is one of the important atherogenic effect of diabetes. Diabetes is accompanied by nonenzymatic glycation of plasma proteins including low density lipoproteins (LDL). Antibody production against modified (glycated) LDL lead to formation of cytotoxic immune complexes. These events may aggravate atherosclerosis. It was supposed that in patients with diabetes there are formation of two times lesions in arteries: atherosclerotic plaques and arteriosclerotic fibrotic plaques complicated with calcium deposition and thrombosis.

About the authors

V. A. Nagornev

Research Institute of Experimental Medicine of the RAMS

Author for correspondence.
Email: shabanov@mail.rcom.ru

академик РАМН

Russian Federation, St. Petersburg

A. D. Denisenko

Research Institute of Experimental Medicine of the RAMS

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

References

  1. Дедов И. И., Балаболкин М. И. Патогенез сахарного диабета // Мед. акад. жури. 2006. Т. 6. № 3. С. 3-15.
  2. Климов А. Н., Денисенко А. Д., Нагорнев В. А. Иммунные комплексы липопротеид-антитело // Иммунореактивность и атеросклероз / Ред. А. Н. Климов. Л., 1986. С. 107-128.
  3. Климов A. Н., Нагорнев В. А., Денисенко А. Д. Изучение иммунологических механизмов развития атеросклероза и новые методы его диагностики и лечения //Мед. акад. журн. 2005. Т. 5. № 2. С. 18-32.
  4. Нагорнев В. А. Патогенез атеросклероза. СПб., 2006.
  5. AbbudZ. A., Shindler D. М., Wilson А. С., RostisJ. В. Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: a statewide study //Am. Heart J. 1995. Vol. 130. P. 51-62.
  6. BlannA. D., Me. Collum C. N. Von Willebrand factor, endothelial cell damage and atherosclerosis H Eur. J. Vase. Surg. 1994. Vol. 8. P. 10-15.
  7. Brown M. S. and Goldstein J. L Lipoprotein metabolism in the macrophage: implication for cholesterol deposition in atherosclerosis // Annu. Rev. Biochem. 1983. Vol. 52. P. 223-261.
  8. Duff G. L., Brechin D. J. and Finkelstein W. E. The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit. IV. The effect of insulin therapy on the inhibition of atherosclerosis in the alloxan-diabetic rabbits // J. Exp. Med. 1954. Vol. 100. P. 371-380.
  9. Goldberg I. J. Why does diabetes increase atherosclerosis I don’t know // J. Clin. Invest. 2004. Vol. 14. P. 613-615.
  10. Gonzalez J., Colwell J. A., Sarji К. E Effect of metabolic control with insulin on plasma von Willebrand factor activity (VI-IIR: WF) in diabetes mellitus H Thromb. Res. 1980. Vol. 17. P. 261-266.
  11. Lorenzi M., Cagiero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus H Diabetes. 1991. Vol. 40. P 653-659.
  12. Nawroth Р., Bierhaus А., Marrero М et al. Atherosclerosis and restenosis: is there а role for RAGE? // Сип. Diab. Rep. 2005. Vol. 5. Р. 11-16.
  13. Neaton J. D., Wentworth D. N., Cutler J. et al. Risk factors death from defferent types of stroke. Multiple Risk Factor Internation Trial Research Group // Ann. Epide¬miol. 1993. Vol.3. Р. 493-497.
  14. О 'Brien Т., Nguyen Т. Т., Hal/away В. J. et al. НDL subparticles and coronary artery disease in NIDDM // Atherosclerosis. 1996. Vol. 121.№2. Р.285-191.
  15. Renard С. et al. Diabetes and diabetes-associated lipid abnoпnalities have distinct effects on initiation and progression of atherosclerotic lesions // J. Clin. Invest. 2004. Vol. 144. Р. 659-668.
  16. Ribau J. С. О., Hatton М W. С., Richardson М Chang¬es in the aortic endothelium and plasma von Willebrand factor levels during the onset and progression of insulin-dependent diabetes in ВВ rats // Atherosclero¬sis. 1998. Vol. 139.Р. 291-299.
  17. Schmidl А. М, Уап S. D., Wautier J. L., Stern D. Acti¬vation of receptor for advanced glycation end products: а mechanism for chronic vascular dysfunction in dia¬betic vasculopathy and atherosclerosis // Circ. Res.1999. Vol. 84. Р. 489-497.
  18. Schmidt А. М, Уап S. D., Уап S. F., Stern D. М Тhе Ьiology of the receptor for advanced glycation end products and its ligands // Biochim. Biophys. Acta. 2000.Vol. 1498. Р. 99-111.
  19. Steiner G., Tkac L, Ujfelman К. D., Lewis G. F. Important contribution of lipoprotein particle number to plasma triglyceride concentration in type 2 diabetes //Atherosclerosis. 1998. Vol. 137.№1. Р.211-214
  20. Siitonen О. /., Niskanen С. R., Laako М et al. Lowerextremity amputations in diabetic and nondiabetic patients. А population based study in easteпn Finland // Diabetes Care. 1993. Vol.16. Р.16--21.
  21. Tedgui А., and Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatoru pathways // Physiol. Rev. 2006. Vol. 86. Р. 515-581.
  22. Wagner D. D. The Weibel-Palade body: Тhе strong granule for von Willebrand factor and P-selectin // Тhromb. Haemost. 1993. Vol. 70. Р. 105-110.
  23. Yamamoto У., Kato /., Doi Т. et al. Development and prevention of advanced diabetic nephropathy in RAGEoverexpressing mice // J. Clin. Invest. 2001. Vol. 108. Р. 261-268.
  24. Уаn S. F., Ramasamy R., Naka У., Schmidt А. М Glycation, inflammation, and RAGE: а scaffold for the macrovascular complications of diabetes and beyond // Circ. Res. 2003. Vol. 93. Р. 1159-1169.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.